MOLECULAR EXPRESS, INC
MOLECULAR EXPRESS, INC is a federal contractor, registered under UEI R1JMHFESEKD5 and CAGE code 337D8. It has been awarded $35,114,556 in federal contracts. Primary work spans Unknown NAICS, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services, Department Of Defense, and Department Of Health And Human Services (hhs).
Contact Information
Registration and classification details
Registration
UEI Code
R1JMHFESEKD5CAGE Code
337D8Entity Structure
Corporate Entity (Not Tax Exempt)Established
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
Molecular Express, Inc. specializes in the design and formulation of novel immunotherapeutic agents and co-adjuvant systems for infectious disease applications, with a focus on TLR7 agonists, HIV immunogens, and vaccine delivery platforms. The company’s core technical expertise lies in molecular for...
Molecular Express, Inc. specializes in the design and formulation of novel immunotherapeutic agents and co-adjuvant systems for infectious disease applications, with a focus on TLR7 agonists, HIV immunogens, and vaccine delivery platforms. The company’s core technical expertise lies in molecular formulation science, immunological adjuvant development, and preclinical biopharmaceutical engineering, particularly in optimizing antigen stability, immune activation profiles, and formulation bioavailability. Their work demonstrates deep proficiency in structure-function analysis of vaccine candidates and the engineering of precision-delivery systems tailored for dendritic cell targeting and sustained immune response modulation. Differentiators include a strong emphasis on translational biotechnology—bridging molecular design with functional immunological outcomes—without reliance on nanotechnology or biotech platforms outside their defined scope. The company maintains a consistent, focused relationship with the Department of Health and Human Services, delivering research and development services aligned with public health priorities in vaccine innovation and infectious disease countermeasures. Their engagements with HHS center on advanced immunogen design and formulation science, indicating a trusted partnership in advancing next-generation prophylactic and therapeutic candidates for high-priority pathogens. Molecular Express operates primarily within NAICS 541714 and 541715, which reflect specialized biotechnology R&D and broader life sciences research excluding nanotechnology. Their market positioning is that of a niche biopharmaceutical R&D firm focused on immunomodulatory formulation science, serving government-funded programs requiring rapid prototyping and preclinical validation of novel vaccine architectures. As a small business structured as a 2L entity based in Rancho Dominguez, California, Molecular Express operates without federal certifications but maintains a focused presence in the U.S. government’s biomedical R&D ecosystem, positioning itself as a responsive, technically agile partner for HHS-led initiatives in vaccine development and immunological innovation.
Key Performance Metrics
Awards Count
45
All time
Active
2
Currently performing
Completed
43
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
Award Analytics & Distribution
Compete with MOLECULAR EXPRESS, INC
Track the contractors you bid against, and the work they win
Award history, agency mix, and NAICS coverage for MOLECULAR EXPRESS, INC
AI-powered matching against your own capabilities and past performance
Teaming and subcontracting signals on every award
Automated alerts when a competitor wins in your market
Join 750+ contractors already using CLEATUS
